CO6150165A2 - Nevos derivados 5,7-disustituidos de [1,3]tiazolo[4,5-d]pirimidin-2 (3h)-ona y su uso en terapia - Google Patents

Nevos derivados 5,7-disustituidos de [1,3]tiazolo[4,5-d]pirimidin-2 (3h)-ona y su uso en terapia

Info

Publication number
CO6150165A2
CO6150165A2 CO09022856A CO09022856A CO6150165A2 CO 6150165 A2 CO6150165 A2 CO 6150165A2 CO 09022856 A CO09022856 A CO 09022856A CO 09022856 A CO09022856 A CO 09022856A CO 6150165 A2 CO6150165 A2 CO 6150165A2
Authority
CO
Colombia
Prior art keywords
compound
nevos
disustituted
tiazolo
pirimidin
Prior art date
Application number
CO09022856A
Other languages
English (en)
Inventor
Rolf Johansson
Sofia Karlstrom
Annika Kers
Gunnar Nordvall
Tobias Rein
Can Slivo
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39230456&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6150165(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of CO6150165A2 publication Critical patent/CO6150165A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Transplantation (AREA)

Abstract

1.- Un compuesto de fórmula (I)donde:R1 representa CH3 o CF3;R2 representa halo, CN o alquilo C1-6;R3 representa H o CH3;R4 representa H o CH3;n representa 0, 1 ó 2; como una base libre o una sal, un solvato o un solvato de una sal farmacéuticamente aceptable del mismo.2.- Un compuesto de la reivindicación 1, donde n representa 1.3.- Un compuesto de la reivindicación 1, donde R1 representa CH3.4.- Un compuesto de la reivindicación 1, donde R2 representa halo o CN.5.- Un compuesto de la reivindicación 1, donde R2 representa F o CI.6.- Un compuesto de la reivindicación 1, donde R2 representa CN.7.- Un compuesto de la reivindicación 1, donde n representa 1; R1 representa CH3; y R2 representa F, CI o CN.8.- Un compuesto de la reivindicación 1, donde la piridina está enlazada en su posición 5 y tiene CI en la posición 2.9.- Un compuesto de la reivindicación 1, donde la piridina está enlazada en su posición 2 y tiene CN en la posición 4.10.- Un compuesto de la reivindicación 1, donde la piridina está enlazada en su posición 2 y tiene F en la posición 5.11.- Un compuesto de la reivindicación 1, donde la piridina está enlazada en su posición 2 y tiene CI en la posición 5.12.- Un compuesto de la reivindicación 1, donde la piridina está enlazada en su posición 2 y tiene F en la posición 3.13.- Un compuesto de la reivindicación 1, donde la piridina está enlazada en su posición 4 y tiene F en la posición 3.14.- Un compuesto de la reivindicación 1, donde R3 representa H.
CO09022856A 2006-09-29 2009-03-05 Nevos derivados 5,7-disustituidos de [1,3]tiazolo[4,5-d]pirimidin-2 (3h)-ona y su uso en terapia CO6150165A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82746006P 2006-09-29 2006-09-29
US82812506P 2006-10-04 2006-10-04

Publications (1)

Publication Number Publication Date
CO6150165A2 true CO6150165A2 (es) 2010-04-20

Family

ID=39230456

Family Applications (1)

Application Number Title Priority Date Filing Date
CO09022856A CO6150165A2 (es) 2006-09-29 2009-03-05 Nevos derivados 5,7-disustituidos de [1,3]tiazolo[4,5-d]pirimidin-2 (3h)-ona y su uso en terapia

Country Status (22)

Country Link
US (2) US7960395B2 (es)
EP (1) EP2069364B1 (es)
JP (1) JP5422386B2 (es)
KR (1) KR101345085B1 (es)
AR (1) AR063023A1 (es)
AT (1) ATE537177T1 (es)
AU (1) AU2007300748B2 (es)
BR (1) BRPI0717109A2 (es)
CA (1) CA2664789A1 (es)
CL (1) CL2007002813A1 (es)
CO (1) CO6150165A2 (es)
ES (1) ES2377469T3 (es)
HK (1) HK1131389A1 (es)
IL (1) IL197293A0 (es)
MX (1) MX2009003005A (es)
NO (1) NO20091579L (es)
NZ (1) NZ576520A (es)
PE (1) PE20080973A1 (es)
RU (1) RU2441012C2 (es)
TW (1) TW200820973A (es)
UY (1) UY30612A1 (es)
WO (1) WO2008039138A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR071036A1 (es) * 2008-03-26 2010-05-19 Astrazeneca Ab Derivados 5, 7-disustituidos de [1, 3]tiazolo[4, 5-d]pirimidin-2 (3h)-ona, una composicion farmaceutica que los comprende y su uso en el tratamiento de enfermedades mediadas por el receptor cx3cr1.
US8476301B2 (en) 2011-09-13 2013-07-02 Eisai R&D Management Co., Ltd. Pyrrolidin-3-ylacetic acid derivative
TWI543975B (zh) 2011-09-13 2016-08-01 Eisai R&D Man Co Ltd Pyrrolidin-3-yl acetic acid derivatives
JP5872105B2 (ja) 2013-03-12 2016-03-01 エーザイ・アール・アンド・ディー・マネジメント株式会社 ピロリジン−３−イル酢酸誘導体の塩およびその結晶
GB201811169D0 (en) 2018-07-06 2018-08-29 Kancera Ab New compounds

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9802729D0 (sv) 1998-08-13 1998-08-13 Astra Pharma Prod Novel Compounds
SE9903544D0 (sv) * 1999-10-01 1999-10-01 Astra Pharma Prod Novel compounds
ATE255584T1 (de) 2000-02-11 2003-12-15 Astrazeneca Ab Pyrimidinverbindungen und ihre verwendung als modulatoren der chemokin-rezeptor-aktivität
GB2359081A (en) 2000-02-11 2001-08-15 Astrazeneca Uk Ltd Pharmaceutically active thiazolopyrimidines
SE0101082D0 (sv) * 2001-03-27 2001-03-27 Astrazeneca Ab Novel use
GB0221829D0 (en) 2002-09-20 2002-10-30 Astrazeneca Ab Novel compound
GB0221828D0 (en) * 2002-09-20 2002-10-30 Astrazeneca Ab Novel compound
AU2004278276B2 (en) 2003-10-07 2007-10-18 Astrazeneca Ab New 2-substituted, 4-amino-thiazolo(4,5-d) pyrimidines, useful as chemokine receptor antagonists, esp. CX3CR1
WO2006064228A2 (en) 2004-12-17 2006-06-22 Astrazeneca Ab Thiazolopyramidine compounds for the modulation of chemokine receptor activity
UA90707C2 (en) 2005-04-06 2010-05-25 Астразенека Аб Novel 5-substituted 7-amino-[1,3]thiazolo[4,5-d]pyrimidine derivatives
AR053347A1 (es) * 2005-04-06 2007-05-02 Astrazeneca Ab Derivados de [1,3]tiazolo[4,5-d]pirimidin-2(3h)-ona 5,7-sustituidos

Also Published As

Publication number Publication date
NZ576520A (en) 2011-08-26
CA2664789A1 (en) 2008-04-03
PE20080973A1 (es) 2008-10-02
WO2008039138A1 (en) 2008-04-03
ES2377469T3 (es) 2012-03-27
US7960395B2 (en) 2011-06-14
AU2007300748B2 (en) 2011-09-08
JP2010504962A (ja) 2010-02-18
BRPI0717109A2 (pt) 2013-10-08
IL197293A0 (en) 2009-12-24
NO20091579L (no) 2009-04-21
CL2007002813A1 (es) 2008-04-04
US20110105537A1 (en) 2011-05-05
HK1131389A1 (en) 2010-01-22
RU2009109100A (ru) 2010-11-10
EP2069364B1 (en) 2011-12-14
RU2441012C2 (ru) 2012-01-27
AU2007300748A1 (en) 2008-04-03
AR063023A1 (es) 2008-12-23
TW200820973A (en) 2008-05-16
EP2069364A4 (en) 2010-03-24
EP2069364A1 (en) 2009-06-17
KR101345085B1 (ko) 2013-12-31
KR20090057069A (ko) 2009-06-03
MX2009003005A (es) 2009-04-01
UY30612A1 (es) 2008-05-02
JP5422386B2 (ja) 2014-02-19
WO2008039138A8 (en) 2009-03-19
US20080318981A1 (en) 2008-12-25
ATE537177T1 (de) 2011-12-15

Similar Documents

Publication Publication Date Title
ECSP099177A (es) Derivados de quinazolinona e isoquinolinona
CO6150166A2 (es) Nuevos derivados de [1,3]tiazolo[4,5-d]pirimidin-2-(3h)-amina 5,7-disustituidos y su uso en terapia
EA200700096A1 (ru) Производные 2-карбамид-4-фенилтиазола, способ их получения и их применение в терапии
NO20082388L (no) Heteroaryl substituerte piperidinderivater som L-CPT1 inhibitorer
CR8505A (es) Derivados de (3-oxo-3,4-dihidroquinoxalin-2-il-amino)-benzamida y compuesto relacionado, como inhibidores de glucogeno fosforilasa para el tratamiento de la diabetes y obesidad
CU23453B7 (es) Pirazolpiridinas sustituidas con carbamato
UY28855A1 (es) Derivados de la 1-amino-ftalazina su preparación y su uso en terapia
TW200608972A (en) Aryl-pyridine derivatives
ECSP088367A (es) Derivados de bifenilo y su uso en el tratamiento de la hepatitis c
EA200800302A1 (ru) Применение производных и аналогов тиазола при лечении рака
DK1996180T3 (da) Benzamid- og pyridylamidderivater som antibakterielle midler
ATE553106T1 (de) Heteroarylpyrrolopyridinone als kinaseinhibitoren
TW200626558A (en) Indazolone derivatives
DE602005023015D1 (de) Indolderivate als viruzide
RS51943B (en) PIPERIDINSKI GPCR AGONIST
TW200800970A (en) Novel cycloalkane carboxamides
NO20070122L (no) Quinazolinonderivater anvendelige som vanilloidantagonister
DE502005008057D1 (de) Substituierte cyclopenten-verbindungen
CY1116885T1 (el) Υποκατεστημενα παραγωγα κυκλοεξυλομεθυλιου
BRPI0519267A2 (pt) derivado de quinolina, seu uso, produÇço e medicamento contendo o mesmo
EA200700901A1 (ru) Производные 2-амидо-4-фенилтиазола, их получение и применение в терапии
CO6150165A2 (es) Nevos derivados 5,7-disustituidos de [1,3]tiazolo[4,5-d]pirimidin-2 (3h)-ona y su uso en terapia
CR8735A (es) Derivados de tetrahidroisoquinolinilsulfonamidas, su preparacion y su utilizacion en terapeutica
HRP20070286T3 (en) Substituted diketopiperazines and their use as oxytocyn antagonists
DK2040703T3 (da) Derivater af 2-benzoylimidazopyridiner, fremstilling deraf og terapeutisk anvendelse deraf